Background In this study, our aim was to describe quality of life (QoL) prevalence and
heterogeneity in QoL reporting in colorectal cancer phase III trials. Methods We included all
phase III trials evaluating anticancer drugs in colorectal cancer patients published between
2012 and 2018 by 11 major journals. Results Out of the 67 publications identified, in 41
(61.2%) QoL was not listed among endpoints. Out of 26 primary publications of trials
including QoL among endpoints, QoL results were not reported in 10 (38.5%). Overall, no …

Methods: We included all primary publications of phase 3 trials evaluating anticancer drugs
in colorectal cancer published between 2012 and 2018 by 11 major journals. We analyzed
QoL inclusion among endpoints, presence of QoL results, and methodology of QoL analysis.
Results: In total, 67 publications were identified (20 in adjuvant/neoadjuvant setting, 26 in
first-line or maintenance and 21 in second and further lines). In 41 (61.2%) publications, QoL
was not listed among endpoints: 17/20 (85.0%) in adjuvant/neoadjuvant setting, 13/26 …